Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
The average prevalence of сhronic heart failure in the adult population, according to the statistics of different countries, ranges from 1.5 % to 5.5 % and therefore the study of this problem and of finding new approaches to the treatment of сhronic heart failure is also still relevant at present....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporozhye State Medical University
2019-12-01
|
| Series: | Patologìâ |
| Subjects: | |
| Online Access: | http://pat.zsmu.edu.ua/article/view/188964/189447 |
| _version_ | 1811322179570106368 |
|---|---|
| author | T. V. Ashcheulova K. M. Kompaniiets N. M. Herasimchuk |
| author_facet | T. V. Ashcheulova K. M. Kompaniiets N. M. Herasimchuk |
| author_sort | T. V. Ashcheulova |
| collection | DOAJ |
| description | The average prevalence of сhronic heart failure in the adult population, according to the statistics of different countries, ranges from 1.5 % to 5.5 % and therefore the study of this problem and of finding new approaches to the treatment of сhronic heart failure is also still relevant at present.
Objective is to show an innovative strategy in the treatment of сhronic heart failure, to show the benefits of using the combined drug sacubitril/valsartan (LCZ696) in comparison with the group of the mentioned above drugs for treating patients with сhronic heart failure and a reduced left ventricular ejection fraction, according to the results of a large randomized clinical research, based on its biochemical properties.
Conclusions. The main positive effects of sacubitril and valsartan in patients with сhronic heart failure are associated with an increase in the amount of the natriuretic peptide and the simultaneous suppression by valsartan of the negative effects of angiotensin II. The indication for the use of the sakubitril / valsartan complex is сhronic heart failure (II – IV FC according to the NYHA classification) in patients with systolic dysfunction in order to reduce the risk of cardiovascular mortality and hospitalization for heart failure. |
| first_indexed | 2024-04-13T13:30:43Z |
| format | Article |
| id | doaj.art-a5352214531a4408b1461365ff2c81c8 |
| institution | Directory Open Access Journal |
| issn | 2306-8027 2310-1237 |
| language | English |
| last_indexed | 2024-04-13T13:30:43Z |
| publishDate | 2019-12-01 |
| publisher | Zaporozhye State Medical University |
| record_format | Article |
| series | Patologìâ |
| spelling | doaj.art-a5352214531a4408b1461365ff2c81c82022-12-22T02:44:59ZengZaporozhye State Medical UniversityPatologìâ2306-80272310-12372019-12-0116340841610.14739/2310-1237.2019.3.188964Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failureT. V. Ashcheulova K. M. KompaniietsN. M. HerasimchukThe average prevalence of сhronic heart failure in the adult population, according to the statistics of different countries, ranges from 1.5 % to 5.5 % and therefore the study of this problem and of finding new approaches to the treatment of сhronic heart failure is also still relevant at present. Objective is to show an innovative strategy in the treatment of сhronic heart failure, to show the benefits of using the combined drug sacubitril/valsartan (LCZ696) in comparison with the group of the mentioned above drugs for treating patients with сhronic heart failure and a reduced left ventricular ejection fraction, according to the results of a large randomized clinical research, based on its biochemical properties. Conclusions. The main positive effects of sacubitril and valsartan in patients with сhronic heart failure are associated with an increase in the amount of the natriuretic peptide and the simultaneous suppression by valsartan of the negative effects of angiotensin II. The indication for the use of the sakubitril / valsartan complex is сhronic heart failure (II – IV FC according to the NYHA classification) in patients with systolic dysfunction in order to reduce the risk of cardiovascular mortality and hospitalization for heart failure.http://pat.zsmu.edu.ua/article/view/188964/189447chronic heart failuresacubitril/valsartanleft ventricular ejection fractionnatriuretic peptideneutral endopeptidase |
| spellingShingle | T. V. Ashcheulova K. M. Kompaniiets N. M. Herasimchuk Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure Patologìâ chronic heart failure sacubitril/valsartan left ventricular ejection fraction natriuretic peptide neutral endopeptidase |
| title | Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure |
| title_full | Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure |
| title_fullStr | Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure |
| title_full_unstemmed | Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure |
| title_short | Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure |
| title_sort | supramolecular complex sacubitril valsartan the first representative of a new class of drugs for the treatment of chronic heart failure |
| topic | chronic heart failure sacubitril/valsartan left ventricular ejection fraction natriuretic peptide neutral endopeptidase |
| url | http://pat.zsmu.edu.ua/article/view/188964/189447 |
| work_keys_str_mv | AT tvashcheulova supramolecularcomplexsacubitrilvalsartanthefirstrepresentativeofanewclassofdrugsforthetreatmentofchronicheartfailure AT kmkompaniiets supramolecularcomplexsacubitrilvalsartanthefirstrepresentativeofanewclassofdrugsforthetreatmentofchronicheartfailure AT nmherasimchuk supramolecularcomplexsacubitrilvalsartanthefirstrepresentativeofanewclassofdrugsforthetreatmentofchronicheartfailure |